NCT01775774

Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome

A Phase 1 Multi-center Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells for the Treatment of Acute Respiratory Distress Syndrome

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Michael A. Matthay · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 1, open label, dose escalation, multi-center clinical trial of Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) for the treatment of Acute Respiratory Distress Syndrome (ARDS). The purpose of this study is to assess the safety of hMSCs in patients with ARDS.

Detailed description

The primary objective of this study is to assess the safety of intravenous infusion of Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) in patients with ARDS.

Conditions

• Acute Respiratory Distress Syndrome

Interventions

Type	Name	Description
BIOLOGICAL	Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells	Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.

Timeline

• Start date: 2013-07-01
• Primary completion: 2014-02-01
• Completion: 2015-02-01
• First posted: 2013-01-25
• Last updated: 2017-08-14
• Results posted: 2017-08-14

Locations

4 sites across 1 country: United States